Last updated: September 6, 2026
Alefacept, marketed as Amevive, was the first biologic approved in the United States for chronic plaque psoriasis. FDA approval came in January 2003, but the product never reached the commercial scale achieved by tumor necrosis factor inhibitors or newer interleukin-targeting therapies. Biogen developed alefacept and later transferred U.S. commercial rights to Astellas. Astellas discontinued U.S. sales in 2011 for commercial reasons, not because of an FDA safety withdrawal. Alefacept has no meaningful current U.S. market, no active biosimilar threat, and limited residual value outside historical clinical and patent analysis.[1-5]
What is alefacept and how does it work?
Alefacept is a recombinant fusion protein consisting of the extracellular domain of human lymphocyte function-associated antigen 3, or LFA-3, linked to the Fc portion of human IgG1. The drug binds CD2 on T lymphocytes and reduces pathogenic memory-effector T-cell activity through immunologic modulation and antibody-dependent cellular cytotoxicity.[1,6]
| Attribute |
Alefacept |
| Brand name |
Amevive |
| Active biologic |
Alefacept |
| Drug class |
LFA-3/IgG1 fusion protein |
| Initial indication |
Moderate-to-severe chronic plaque psoriasis |
| FDA approval |
January 30, 2003 |
| Sponsor at approval |
Biogen |
| Administration |
Intramuscular injection |
| Standard course |
Weekly dosing for 12 weeks |
| U.S. status |
Commercially discontinued in 2011 |
| Main historical competitors |
Enbrel, Raptiva, Humira, Remicade, Stelara |
| Current commercial position |
No material U.S. sales |
Alefacept was administered as a finite 12-week course rather than as continuous maintenance therapy. That dosing model reduced cumulative treatment exposure but also limited recurring revenue per patient and made the product less attractive than chronic biologics with ongoing maintenance schedules.
When did alefacept lose market exclusivity?
Alefacept lost commercial relevance before generic or biosimilar competition became the primary issue. The product was withdrawn from the U.S. market in 2011, approximately eight years after approval. Its commercial discontinuation occurred before the modern U.S. biosimilar market developed.[2,3]
The FDA approval did not create the same regulatory exclusivity profile used for current biologics under the Biologics Price Competition and Innovation Act. Alefacept was approved in 2003 as a biologic product under the pre-BPCIA framework. The FDA did not establish an Orange Book-style, product-specific patent listing system for biologics comparable to the system used for small-molecule drugs.[7,8]
Alefacept exclusivity timeline
| Date |
Event |
| January 2003 |
FDA approves Amevive for adults with moderate-to-severe chronic plaque psoriasis |
| 2003-2005 |
Product competes with Enbrel and emerging psoriasis biologics |
| 2006 |
Astellas assumes U.S. commercialization under a rights arrangement with Biogen |
| 2008 |
Raptiva is withdrawn from the U.S. market, changing the psoriasis competitive environment |
| 2009-2010 |
Stelara and other newer mechanisms increase competitive pressure |
| 2011 |
Astellas discontinues U.S. marketing of Amevive for commercial reasons |
| Post-2011 |
No meaningful U.S. commercial relaunch or biosimilar market develops |
The relevant commercial endpoint is therefore the 2011 discontinuation, not a later generic-entry date.
What were alefacept’s FDA regulatory milestones?
The FDA approved alefacept for adults with moderate-to-severe chronic plaque psoriasis who were candidates for systemic therapy or phototherapy. The approval was based on clinical studies showing that a subset of patients achieved a clinically meaningful reduction in psoriasis severity, including a Psoriasis Area and Severity Index response.[1]
Alefacept had important product characteristics that affected its market performance:
- It required weekly intramuscular administration.
- Treatment was generally delivered in 12-week courses.
- Patients required lymphocyte monitoring because of the drug’s T-cell effects.
- The label included warnings and precautions relating to malignancy, infections, hypersensitivity, and lymphocyte reduction.
- It was not approved for pediatric use.
- It did not provide the broad inflammatory disease franchise available to some tumor necrosis factor inhibitors.
The FDA did not withdraw the product for a newly identified safety signal. Astellas stated that the discontinuation reflected commercial considerations. The difference matters for residual franchise value: products terminated for safety concerns face a more severe regulatory overhang, while products discontinued for commercial reasons may retain limited licensing or regional value.[2,3]
How did alefacept perform financially?
Alefacept had a short and modest commercial trajectory. Public company disclosures did not establish a durable, separately reported revenue stream comparable with major psoriasis biologics. Biogen reported company-level revenue and product performance, but Amevive did not become a major contributor to total corporate sales. After Astellas assumed U.S. commercialization, public reporting also did not identify Amevive as a material revenue driver.[9,10]
Financial trajectory
| Period |
Commercial condition |
Financial implication |
| 2003 launch |
First approved biologic for psoriasis |
Initial novelty and first-mover benefit |
| 2004-2006 |
Increasing biologic competition |
Limited share expansion and modest franchise contribution |
| 2006 rights transfer |
Astellas assumes U.S. commercial role |
Biogen reduces direct commercial exposure |
| 2007-2010 |
Newer agents improve convenience and efficacy |
Revenue pressure increases |
| 2011 |
U.S. discontinuation |
Product revenue effectively exits the U.S. market |
| After 2011 |
No active U.S. commercial franchise |
No meaningful recurring U.S. revenue |
The core economic problem was limited patient lifetime value. Alefacept’s 12-week treatment course created less recurring revenue than chronic biologic regimens. Its intramuscular administration was also less attractive than self-administered subcutaneous products. In a market where physicians and payers increasingly evaluated durable skin clearance, convenience, and dosing flexibility, alefacept offered a weaker commercial proposition.
No reliable public evidence supports a material post-2011 revenue stream. The product’s financial value shifted from operating revenue to residual intellectual property, clinical data, manufacturing knowledge, and possible regional rights.
How did alefacept compare with competing psoriasis biologics?
Alefacept entered a rapidly expanding psoriasis biologic market. Its initial competitive advantage was timing, but the advantage was temporary.
| Product |
Mechanism |
Initial U.S. approval |
Commercial characteristics relative to alefacept |
| Amevive |
LFA-3/IgG1 fusion protein |
2003 |
Finite 12-week course; intramuscular dosing |
| Enbrel |
TNF inhibitor |
2004 for psoriasis |
Established platform and broader inflammatory indications |
| Raptiva |
Anti-CD11a antibody |
2003 |
Competing T-cell mechanism; withdrawn in 2009 |
| Humira |
TNF inhibitor |
2008 for psoriasis |
Strong physician familiarity and broad label |
| Remicade |
TNF inhibitor |
2006 for psoriasis |
High efficacy and infusion-center model |
| Stelara |
IL-12/23 inhibitor |
2009 |
Less frequent dosing and strong efficacy |
| Cosentyx |
IL-17A inhibitor |
2015 |
Later-generation efficacy benchmark |
| Tremfya |
IL-23 inhibitor |
2017 |
Durable response and infrequent maintenance dosing |
Alefacept’s response rates were generally lower than those associated with later IL-17 and IL-23 therapies. The product also lacked the broad, multi-indication commercial leverage available to Humira, Enbrel, and Remicade. Those factors reduced payer, physician, and manufacturer incentives to preserve the franchise.
What patent protection covered alefacept?
Alefacept’s patent position centered on the underlying LFA-3 immunoglobulin fusion-protein technology, recombinant production methods, pharmaceutical compositions, and therapeutic use. The estate was more important during development and early commercialization than after the market became dominated by alternative biologic mechanisms.
Because alefacept was discontinued before the modern biosimilar wave, patent expiry did not produce a conventional U.S. generic-entry event. Biologics do not have traditional small-molecule generics, and any follow-on product would have required a biologics licensing pathway or another applicable regulatory route.
Patent and exclusivity assessment
| Issue |
Assessment |
| Small-molecule generic risk |
Not applicable |
| Biosimilar risk |
Theoretical but commercially immaterial after discontinuation |
| Orange Book listing |
No conventional Orange Book patent-blocking framework for the biologic |
| Core patent subject matter |
LFA-3/IgG fusion proteins, compositions, uses, production |
| Commercial patent value |
Limited after U.S. discontinuation |
| Manufacturing barrier |
Potentially meaningful because recombinant fusion proteins require validated cell culture, purification, analytics, and comparability data |
| Litigation leverage |
Low after withdrawal absent a proposed commercial follow-on product |
A competitor seeking to develop an alefacept-like product would face more than patent questions. It would need to establish a viable clinical and commercial rationale in a psoriasis market with highly effective IL-17 and IL-23 therapies. That market barrier is more significant than any residual patent uncertainty.
What is the Orange Book and Purple Book status of alefacept?
The Orange Book is principally a reference for approved drugs and patent or exclusivity information relevant to small-molecule products. Alefacept was a biologic, so the Orange Book was not the principal source for its patent status.[7]
The Purple Book is the FDA reference for licensed biological products and biosimilar or interchangeable biological-product information. Alefacept’s historical approval predates the current commercial biosimilar landscape, and it has not generated an active biosimilar competition set comparable with products such as Neupogen, Remicade, Humira, or Stelara.[8]
The practical status is:
- No active U.S. branded franchise.
- No material current biosimilar launch threat.
- No active generic substitution pathway.
- No meaningful Orange Book litigation pathway.
- No current commercial incentive to challenge legacy alefacept patents.
Which companies challenged alefacept?
No company became a material U.S. Paragraph IV challenger to Amevive. Paragraph IV litigation is a Hatch-Waxman mechanism associated primarily with small-molecule abbreviated new drug applications. It was not the normal pathway for an alefacept follow-on product.
There is also no material public record of a biosimilar litigation campaign directed at alefacept. The product’s discontinuation removed the economic target before biosimilar developers had a strong incentive to invest in clinical development, regulatory filings, and manufacturing scale-up.
What manufacturing and intellectual-property barriers remain?
Alefacept manufacturing would require production of a recombinant fusion protein with controlled glycosylation, aggregation, potency, purity, and immunogenicity characteristics. A follow-on developer would need a reference product strategy, analytical comparability package, process development program, and clinical or pharmacodynamic evidence appropriate to the regulatory pathway.
The manufacturing barrier is therefore real but not commercially decisive. The principal obstacle is demand. Physicians now have access to agents with stronger efficacy, longer dosing intervals, and broader reimbursement experience. Recreating alefacept would require a cost structure low enough to offset its weaker clinical positioning, which would be difficult without a differentiated indication or low-cost regional strategy.
What licensing deals affected alefacept?
Biogen developed alefacept and later entered into a commercial arrangement under which Astellas handled U.S. marketing. This transfer reflected the product’s limited scale relative to the parties’ larger portfolios. Astellas subsequently discontinued U.S. commercialization in 2011.[2,9,10]
The transaction illustrates a recurring pattern in biologic portfolio management: a product can remain clinically viable while becoming commercially noncore. When sales, manufacturing complexity, monitoring requirements, and competitive intensity no longer justify direct commercialization, rights can be transferred or abandoned.
No major post-discontinuation licensing transaction has restored alefacept as a significant commercial product.
What is the current commercial outlook for alefacept?
Alefacept has no credible pathway to a meaningful U.S. commercial recovery under its original psoriasis positioning. A relaunch would face:
- A crowded and clinically superior psoriasis market.
- Limited physician familiarity after more than a decade off the market.
- Reimbursement disadvantage against established biologics.
- Manufacturing and supply-chain redevelopment costs.
- A need for new evidence in modern treatment algorithms.
- No clear pricing advantage sufficient to compensate for weaker efficacy or convenience.
Potential residual value could exist in academic research, immunology platform analysis, or highly targeted regional licensing. Those opportunities are distinct from a conventional branded-drug recovery thesis.
Key Takeaways
- Alefacept, marketed as Amevive, received FDA approval in January 2003 for chronic plaque psoriasis.
- Astellas discontinued U.S. sales in 2011 for commercial reasons, not because of an FDA safety withdrawal.
- The product had limited revenue scale and never became a major contributor to Biogen or Astellas.
- A 12-week intramuscular treatment course reduced recurring revenue potential.
- Newer TNF, IL-12/23, IL-17, and IL-23 therapies displaced alefacept on efficacy, dosing convenience, and commercial breadth.
- Alefacept did not generate a material Paragraph IV or biosimilar challenge market.
- Its remaining IP and manufacturing knowledge have limited practical value without a differentiated clinical or regional strategy.
- The product has no meaningful current U.S. revenue trajectory.
FAQs About Alefacept
Is alefacept still available in the United States?
No. Astellas discontinued U.S. marketing of Amevive in 2011.
Was alefacept withdrawn because it was unsafe?
No. The discontinuation was attributed to commercial reasons rather than an FDA safety withdrawal.
Did alefacept have a biosimilar competitor?
No commercially significant alefacept biosimilar reached the U.S. market.
Why did alefacept fail commercially despite being an approved biologic?
Its finite 12-week course, intramuscular administration, monitoring requirements, lower efficacy than later biologics, and lack of broad indications limited its commercial potential.
Could alefacept be relaunched for psoriasis?
A relaunch is commercially unlikely without a new clinical advantage, major price differentiation, or a niche indication. Current psoriasis therapies provide stronger competitive benchmarks for efficacy, convenience, and treatment durability.
References
- U.S. Food and Drug Administration. (2003). Amevive (alefacept) prescribing information.
- Astellas Pharma Inc. (2011). Amevive discontinuation announcement and product information.
- U.S. Food and Drug Administration. (2011). Biological product and drug safety communications concerning Amevive.
- Krueger, G. G., Papp, K. A., Stough, D. B., Loven, K. H., Gulliver, W. P., Ellis, C. N., et al. (2002). A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of alefacept in patients with chronic plaque psoriasis. Archives of Dermatology, 138(5), 592-600.
- Menter, A., Griffiths, C. E. M. (2007). Current and future management of psoriasis. The Lancet, 370(9583), 272-284.
- Ellis, C. N., Krueger, G. G. (2001). Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. New England Journal of Medicine, 345(4), 248-255.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- Biogen Idec Inc. (2003-2006). Annual reports and Form 10-K filings.
- Astellas Pharma Inc. (2006-2011). Annual reports and securities filings.
